1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) is sponsored by National Heart, Lung, and Blood Institute (NHLBI) / NIH. This program supports small businesses in accelerating the commercialization of technologies for heart, lung, blood, and sleep disorders.
It is a Phase IIB Bridge Award, indicating it targets projects that have already demonstrated success in earlier SBIR/STTR phases.
Get alerted about grants like this
Save a search for “National Heart, Lung, and Blood Institute (NHLBI) / NIH” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) | Research Funding National Institutes of Health NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) The Small Business Innovation Research (SBIR) Program is an important funding mechanism that the National Institutes of Health (NIH) uses to develop innovative solutions that address public health challenges.
A major objective of the program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of biomedical products is often impeded by a significant funding gap between the end of the SBIR Phase II award and the commercialization stage.
This Notice of Funding Opportunity (NOFO) invites SBIR grant applications from SBCs to support later-stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR Phase II awards and which will require eventual Federal regulatory approval/clearance.
The purpose of this NOFO and the resulting Phase IIB awards is to assist applicants in pursuing the milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between SBIR Phase II awardees and third-party investors and/or strategic partners. Projects proposed under this NOFO MUST be relevant to the NHLBI mission (see B. Scientific/Technical Scope).
This NOFO is specifically intended to benefit clinical practice by accelerating the commercialization of novel products that require ultimate approval/clearance by a Federal regulatory agency.
This NOFO will give competitive preference and funding priority to applications deemed likely to result in a clinically-relevant commercial product as indicated by the applicant’s ability to secure independent third-party investor funds that equal or exceed the requested NHLBI funds, and competitive preference and funding priority to applications that show a strong potential for clinically relevant commercial products, as evidenced by the applicant’s ability to secure independent third-party investor funds equal to or exceeding the total requested costs.
Letter of Intent Due Date(s): January 26, 2025; Renewal / Resubmission / Revision Due Date(s): Feb. 26, 2025; RFA-HL-26-014 Expiration Date New Date November 17, 2025 per issuance of NOT-OD-26-006 . Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.
Total funding support (direct costs, indirect costs, fee) for the entire budget period MUST not exceed $3,500,000. For any single year of the project period, it is recommended that the budget not exceed $1,166,667 total funding support.
Applicants that intend to request budgets greater than $1,166,667 total funding support in any year are strongly encouraged to communicate with the Scientific / Research Contact(s) listed under Section VII before applying. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project. Medical - Clinical Science
According to the current listing, eligibility includes: Small businesses. Confirm the full requirements in the official notice before applying.
Applications for NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) are due February 27, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) is funded by National Heart, Lung, and Blood Institute (NHLBI) / NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Growing Data-science Research in Africa to Stimulate Progress (GRASP) is sponsored by National Heart, Lung, and Blood Institute (NHLBI) / NIH. The GRASP program supports data-science research in Africa to stimulate progress. While the provided information is an award notice, it indicates an active program with a performance end date in July 2026, suggesting ongoing or upcoming related opportunities. The NIH supports a diverse mix of research projects in Sub-Saharan Africa.
NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) is sponsored by National Heart, Lung, and Blood Institute (NHLBI) / NIH. This Notice of Funding Opportunity invites small businesses to submit SBIR grant applications to support later stage research and development (Phase IIB) for promising projects that were previously funded by SBIR or STTR Phase II awards and address rare diseases or young pediatr…
Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed) is sponsored by National Heart, Lung, and Blood Institute (NHLBI) / NIH. This NOFO invites eligible United States small business concerns (SBCs) to submit STTR Phase I and Fast-Track grant applications. The NHLBI will support Phase I and Fast-Track applications from early-career scientists and investigators with data science, artificial intelligence/machine learning, engineering, clinical care and other biomedical backgrounds who are new to the NIH SBIR/STTR programs. Applications submitted to this NOFO are not allowed to propose clinical trial(s).
NIH's June 1 omnibus reset added Direct-to-Phase II to the STTR program for the first time. The change compresses university spinouts' funding timeline from three years to fifteen months, but the 30% research-institution subaward, feasibility-evidence rules, and IP licensing mechanics are not yet sorted at most universities.
Read articleNIH committed $402 million across 601 multiyear-funded grants in the first eight months of FY 2026 — more than four times the pace of two years ago. The mechanism front-loads obligations into a single fiscal year, leaving less budget for new project starts and squeezing FY 2026 success rates. What researchers and institutions should be doing now.
Read articlePAR-26-042 funds NLM-priority clinical informatics R01 grants up to $250,000 in direct costs per year through March 6, 2029, with standard NIH cycles on October 5, February 5, and June 5. The notice explicitly defines non-responsive applications: incremental tool improvements, projects primarily focused on social determinants of health, and projects primarily focused on ethical/legal/social issues. With NIH SBIR/STTR just reopened and the OMB Uniform Grants Regulation rewrite reshaping discretionary awards, the NLM clinical informatics line is one of the few stable, well-defined biomedical funding streams left at the agency. Here is how to read it.
Read article